Stock JUNO THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Juno Therapeutics Inc

Equities

US48205A1097

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide
RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide
RE
Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid
RE
Gilead Sciences : Sangamo in $3 billion gene-editing deal with Gilead
RE
Juno Therapeutics : Celgene Receives Antitrust Clearance for Juno Acquisition
BU
Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
WeissLaw LLP : Investigates Juno Therapeutics Inc. Acquisition
PR
Stocks hit record as senators reach deal to end shutdown
RE
JUNO THERAPEUTICS, INC. Former SEC Attorney Willie Briscoe Believes the Acquisition by Celgene Corporation May be Unfair to Shareholders
BU
Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion
RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
Celgene Corporation : to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
BU
JUNO THERAPEUTICS INVESTIGATION by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO
BU
JUNO THERAPEUTICS INVESTIGATION by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO
BU
Juno Therapeutics : Names Cindy Elkins as Chief Information Officer
BU
Juno Therapeutics : to Present at the 36th Annual J.P. Morgan Healthcare Conference
BU
Juno Therapeutics : and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership
PR
Juno Therapeutics : Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH
BU
Juno Therapeutics : Highlights Key Translational Insights with JCAR017 in Patients with DLBCL
BU
Juno Therapeutics : Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Juno Therapeutics Inc